Nasus Pharma Ltd.

As of June 30, 2026, Nasus Pharma Ltd. carries a market capitalization of 40.99M, placing it among publicly traded companies globally. Its enterprise value stands at 29.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nasus Pharma Ltd.'s next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2026, Nasus Pharma Ltd. has 11.71M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Nasus Pharma Ltd. maintains a current ratio of 8.77, meaning it holds 8.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Nasus Pharma Ltd.'s stock has declined approximately 56.99% over the past 52 weeks. The 50-day moving average sits at 3.62, while the 200-day moving average is 3.77.

As of June 30, 2026, Nasus Pharma Ltd. holds 11.82M in cash and equivalents against 103,000.00 in total debt, resulting in a net debt position of -7.82M. Total book value stands at 11.00M, with working capital of 10.91M providing operational flexibility.